跳至主要内容
临床试验/DRKS00030569
DRKS00030569尚未招募4 期

Efficacy of DeflaGyn® vaginal gel in the treatment of suspicious cervical smear findings, related histopathological diagnoses CIN1 and CIN2 and the hr-HPV status: a post marketing clinical follow-up study. - DEFLACIN-002

Exeltis Germany GmbH0 个研究点目标入组 70 人开始时间: 2022年10月20日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
Female

入选标准

  • 1. Female premenopausal patients between 35 and 50 years
  • 2. Cytologic diagnosis ASC-US, ASC-H, LSIL or HSIL
  • 3. Histologic Diagnosis of CIN1 or CIN2
  • 4. Positive for hr-HPV
  • 5. Written Informed Consent

排除标准

  • 1. Oncological or immunological disease
  • 2. Chronic viral disease
  • 3. Immunosuppressive treatment
  • 4. Pregnancy
  • 5. Patients who are postmenopausal
  • 6. Known Allergy to the gel or one of its components
  • 7. Colposcopic finding conspicuous of invasive disease
  • 8. Unsatisfactory colposcopy
  • 9. For CIN1 patients: risk discrepancy with cytological findings (e.g. HSIL; ASC-H)
  • 10. Benign or malignant gynecological changes of the vulva
  • 11. Simultaneous participation at another clinical trial or during participation during the preceding 6 months

研究者

发起方
Exeltis Germany GmbH

相似试验